Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient - Related Studies

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

This study has been completed.

Study NCT00002025. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cytomegalovirus Infections
		Cytomegalovirus Retinitis
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Communicable Diseases
		Infection
		Retinitis

3	More general conditions related to this trial
		DNA Virus Infections
		Eye Diseases
		Eye Infections
		Eye Infections, Viral
		Herpesviridae Infections
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retinal Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Ganciclovir

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antiviral Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Hoffmann-La Roche